CFRX · Contrafect Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $44.74M | $35.51M | $22.61M | $18.06M | $22.42M | $17.31M |
| SG&A | $12.15M | $11.76M | $11.63M | $9.81M | $8.71M | $9.25M |
| Total Operating Expenses | $64.61M | $47.27M | $34.24M | $27.87M | $31.12M | $26.56M |
| D&A | $154.0K | $148.0K | $168.2K | $169.2K | $151.3K | $187.2K |
| Operating Income | ($64.61M) | ($47.27M) | ($34.24M) | ($27.87M) | ($31.12M) | ($26.56M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($65.15M) | ($20.28M) | ($28.16M) | ($12.79M) | ($37.68M) | ($15.52M) |
| EPS - Basic | ($98.95) | - | - | - | - | - |
| EPS - Diluted | ($98.95) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.91M | $16.65M | $15.48M | $24.18M | $8.32M | $7.00M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $13.67M | $2.39M | $1.81M | $2.62M | $1.43M | $1.30M |
| Current Assets | $17.71M | $62.86M | $46.65M | $30.76M | $31.44M | $48.70M |
| Total Assets | $20.68M | $66.76M | $51.12M | $35.01M | $32.87M | $50.19M |
| Current Liabilities | $20.84M | $12.17M | $6.06M | $10.06M | $5.80M | $4.42M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $32.53M | $17.39M | $38.50M | $19.46M | $27.33M | $19.00M |
| Stockholders' Equity | ($11.85M) | $49.38M | $12.62M | $15.54M | $5.54M | $31.19M |
| Retained Earnings | ($325.70M) | ($260.55M) | ($240.27M) | ($212.11M) | ($199.32M) | ($161.64M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($45.97M) | ($41.13M) | ($33.19M) | ($27.43M) | ($29.30M) | ($24.53M) |
| Investing Cash Flow | $32.08M | ($11.61M) | ($27.40M) | $21.97M | ($8.97M) | ($9.36M) |
| Financing Cash Flow | $6.14M | $53.91M | $51.89M | $21.32M | $32.10M | $37.08M |
| CapEx | $62.0K | - | - | $20.0K | $133.5K | - |
| Free Cash Flow | ($46.04M) | - | - | ($27.45M) | ($29.43M) | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.71 | - | - | 2.15 | 0.78 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -315.1% | -30.4% | -55.1% | -36.5% | -114.6% | -30.9% |
| Return on equity | 549.7% | -41.1% | -223.1% | -82.3% | -680.0% | -49.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.85 | 5.16 | 7.70 | 3.06 | 5.42 | 11.02 |
| Quick ratio | 0.85 | 5.16 | 7.70 | 3.06 | 5.42 | 11.02 |
| Cash ratio | 0.43 | 1.37 | 2.56 | 2.40 | 1.44 | 1.58 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -1.74 | 1.35 | 4.05 | 2.25 | 5.93 | 1.61 |
| Liabilities / Assets | 1.57 | 0.26 | 0.75 | 0.56 | 0.83 | 0.38 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -36.7% | -38.0% | -22.9% | 10.5% | -17.2% | 20.8% |
| Net income growth (YoY) | -221.2% | 28.0% | -120.1% | 66.0% | -142.8% | 45.6% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 6.7% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 291.3% | -18.8% | 180.5% | -82.2% | 59.9% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CONTRAFECT Corp against the 5 most active filers in the same SIC group.